PRAME and breast cancer: To further validate the prognostic significance of LMO1, PRAME, and RSPO2, we also verified the expression levels of the three genes in the metastatic BC dataset [13], confirming that LMO1, PRAME, and RSPO2 were consistently overexpressed in Cluster 2 showing worst survival (Figure 3), reinforcing their roles as key prognostic biomarkers.